Results 61 to 70 of about 9,247 (168)

Unusual Cutaneous and Lymphatic Findings in an Adult Patient

JEADV Clinical Practice, EarlyView.
Sarah Preis, Mara Hubbuch, Susanne Annette Steimle‐Grauer, Tilo Biedermann, Oana‐Diana Persa   +4 more
wiley   +1 more source

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

Asian Journal of Transfusion Science, 2017
Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 ...
Mei-Hwa Lin, Fei-Yun Liu, Hsiu-Mien Wang, Hsin-Ching Cho, Shyh-Chyi Lo   +4 more
doaj   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

P28 | ON DEMAND PLERIXAFOR FOR STEM CELL MOBILIZATION WITH G-CSF ONLY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB: A SINGLE CENTER EXPERIENCE

Haematologica
Daratumumab is increasingly used as a part of the induction therapy in patients with newly diagnosed multiple myeloma (NDMM) and is associated with deeper responses to treatment.
B. Skopec, L. Cemazar, M. Skerget
doaj   +1 more source

Circadian Deregulation in Multiple Myeloma: BMAL1/CLOCK Expression Patterns and Diagnostic Performance

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Background Circadian clock disruption has emerged as a relevant axis in cancer; however, the expression patterns and diagnostic relevance of BMAL1 and CLOCK in multiple myeloma (MM) remain insufficiently defined. Methods BMAL1 and CLOCK mRNA expression was quantified by RT‐qPCR in bone marrow samples from 46 newly diagnosed MM patients and 13 ...
Hamide Albayrak, Mustafa Ertan Ay, Anıl Tombak, Kenan Çevik, Özlem İzci Ay, Tuba Kabasakal, Mehmet Emin Erdal   +6 more
wiley   +1 more source

Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab

Haematologica
Daratumumab is an anti-CD38 monoclonal antibody that has shown clinical benefit in both relapsed/refractory as well as newly diagnosed multiple myeloma (MM).
Guido Lancman, Dahniel Sastow, Minira Aslanova, Erin Moshier, Hearn Jay Cho, Sundar Jagannath, Samir Parekh, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Ajai Chari   +13 more
doaj   +1 more source

Systemic Therapy for Paediatric Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Current Evidence and Limitations

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim The role of systemic therapy in paediatric Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) remains undefined. Management is primarily guided by observational data and variable practice patterns. This systematic review aims to integrate recent evidence and evaluate clinical outcomes associated with systemic therapies in ...
Samantha Ting, Kangjie Reuel Chua, Li‐Chuen Wong, Gloria Fong   +3 more
wiley   +1 more source

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN)

American Journal of Hematology, Volume 101, Issue 9, Page 2353-2370, September 2026.
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W. C. J. van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson, Charlotte Pawlyn, María‐Victoria Mateos, Sonja Zweegman, Martin Schreder, Meral Beksaç, Christoph Driessen, Enrique M. Ocio, Rakesh Popat, Leo Rasche, Cyrille Touzeau, Pellegrino Musto, Annemiek Broijl, Meletios Dimopoulos, Roman Hajek, Mario Boccadoro, Pieter Sonneveld   +25 more
wiley   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 5, Page 625-634, September 2026.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source